Page last updated: 2024-09-05

lapatinib and Epithelial Neoplasms

lapatinib has been researched along with Epithelial Neoplasms in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alloisio, M; Fatuzzo, G; Lorenzi, E; Rubino, L; Santoro, A; Simonelli, M; Suter, MB; Zucali, PA1
Armstrong, DK; Carolla, RL; Fischer, EG; Garcia, AA; Godwin, AK; Lankes, HA; Leslie, KK; Liepman, MK; Mannel, RS; Sill, MW; Spirtos, NM1
Blanc-Fournier, C; Bourgeois, H; Briand, M; Clarisse, B; Fabbro, M; Joly, F; Krieger, S; Leconte, A; Lheureux, S; Lortholary, A; Pautier, P; Petit, T; Plantade, A; Richard, N; Selle, F; Vilquin, P; Weber, B1

Reviews

1 review(s) available for lapatinib and Epithelial Neoplasms

ArticleYear
Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports.
    Future oncology (London, England), 2015, Volume: 11, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Histone Deacetylase Inhibitors; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Quinazolines; Receptor, IGF Type 1; Receptors, Somatomedin; Sorafenib; Thymus Neoplasms; TOR Serine-Threonine Kinases; Young Adult

2015

Trials

2 trial(s) available for lapatinib and Epithelial Neoplasms

ArticleYear
A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.
    Gynecologic oncology, 2012, Volume: 124, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Disease-Free Survival; ErbB Receptors; Female; Humans; Ki-67 Antigen; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Polymorphism, Genetic; Quinazolines

2012
Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2012, Volume: 22, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; Humans; Lapatinib; Metabolome; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Quinazolines; Recurrence; Risk Assessment; Topotecan; Treatment Outcome; Young Adult

2012